In vitro Activity of Cefiderocol and Ceftazidime-Avibactam, Against Carbapenemase-Producing Enterobacterales

被引:2
|
作者
Ozyurt, Ozlem K. [1 ]
Tufanoglu, Pinar [1 ]
Cetinkaya, Ozgul [2 ]
Ozhak, Betil [1 ]
Yazisiz, Hatice [1 ]
Ongut, Gozde [1 ]
Turhan, Ozge [3 ]
Ogunc, Dilara [1 ]
机构
[1] Akdeniz Univ, Fac Med, Dept Med Microbiol, Antalya, Turkey
[2] Univ Hlth Sci, Antalya Training & Res Hosp, Dept Med Microbiol, Antalya, Turkey
[3] Akdeniz Univ, Fac Med, Dept Infect Dis & Clin Microbiol, Antalya, Turkey
关键词
RESISTANCE; COLISTIN;
D O I
10.7754/Clin.Lab.2022.220827
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Background: Carbapenemase production is an issue of significant clinical and public health concern, because of the shortage of effective antimicrobial agents available for treatment. Here, we present antimicrobial susceptibili-ty data of ceftazidime-avibactam, cefiderocol, and other clinically relevant antibiotics for carbapenemase-produc-ing Enterobacterales bloodstream isolates, in accordance with European Committee on Antimicrobial Susceptibili-ty Testing (EUCAST) guidelines. Methods: A total of 133 carbapenemase producing Enterobacterales bloodstream isolates from May 2010 to Sep-tember 2018 were included in the study. Species were identified using matrix-assisted laser-desorption ionization time-of-flight mass spectrometry (Bruker Daltonics, Germany). The presence of the blaKPC, blaNDM, blaOXA-48, blaVIM, and blaIMP carbapenemase genes were investigated by BD Max CRE assay (Becton Dickinson, USA) and in-house PCR. Antimicrobial susceptibility testing was performed by the BD Phoenix automated system (Becton Dickinson, USA), except cefiderocol and colistin. Cefiderocol and colistin susceptibility was determined by disk diffusion and broth microdilution method, respectively. Results: Except for cefiderocol and ceftazidime-avibactam, the percentage of susceptible isolates did not exceed 90% for any of the antibiotics tested. Although none of the isolates were resistant to cefiderocol, the ceftazidime-avibactam resistance rate was 9.8%. All of the ceftazidime-avibactam resistant strains were NDM (New Delhi metallo-beta-lactamases) producers. Among the other clinically relevant antibiotics tested, only amikacin, colistin, tigecycline, and fosfomycin susceptibility rates exceeded 50%. Of the 133 isolates 22.6% were resistant to colistin which is the preferred antibiotic with a second active agent for infections caused by metallo-beta-lactamase pro-ducing Enterobacterales in Turkey. Conclusions: In our study, resistance to ceftazidime-avibactam was detected only in metallo-beta-lactamase pro-ducing Enterobacterales isolates, while cefiderocol was found to be effective against all strains. It is important to monitor regional antimicrobial susceptibility data, as the emergence of antimicrobial resistant phenotypes is di-rectly linked to the use of any given antimicrobial agent.
引用
收藏
页码:155 / 160
页数:6
相关论文
共 50 条
  • [21] Ceftazidime-Avibactam Improves Outcomes in High-Risk Neutropenic Patients with Klebsiella pneumoniae Carbapenemase-Producing Enterobacterales Bacteremia
    Herrera, Fabian
    Torres, Diego
    Laborde, Ana
    Jordan, Rosana
    Manez, Noelia
    Berruezo, Lorena
    Lambert, Sandra
    Suchowiercha, Nadia
    Costantini, Patricia
    Nenna, Andrea
    Pereyra, Maria Laura
    Benso, Jose
    Ibanez, Maria Luz Gonzalez
    Eusebio, Maria Jose
    Barcan, Laura
    Baldoni, Nadia
    Tula, Lucas
    Rossi, Ines Roccia
    Luck, Martin
    Soto, Vanesa
    Fernandez, Veronica
    Carena, Alberto angel
    MICROORGANISMS, 2024, 12 (01)
  • [22] In vitro Synergistic Activity of Ceftazidime-Avibactam in Combination with Aztreonam or Meropenem Against Clinical Enterobacterales Producing blaKPC or blaNDM
    Kuai, Junyang
    Zhang, Yawei
    Lu, Binghuai
    Chen, Hongbin
    Zhang, Yulin
    Li, Henan
    Wang, Yuanyuan
    Wang, Qi
    Wang, Hui
    Wang, Xiaojuan
    INFECTION AND DRUG RESISTANCE, 2023, 16 : 3171 - 3182
  • [23] Evaluation of In Vitro Activity of Ceftolozane-tazobactam and Ceftazidime-avibactam Against Carbapenemase-producing Multi-drug Resistant Klebsiella pneumoniae Isolates
    Terzi, Huseyin Agah
    Aydemir, Ozlem
    Demiray, Tayfur
    Koroglu, Mehmet
    Altindis, Mustafa
    MEDITERRANEAN JOURNAL OF INFECTION MICROBES AND ANTIMICROBIALS, 2020, 9
  • [24] Ceftazidime-avibactam in urinary tract infections due to carbapenemase-producing Klebsiella in kidney transplantation
    Caravaca-Fontan, Fernando
    Jimenez-Alvaro, Sara
    Marcen-Letosa, Roberto
    Fernandez-Rodriguez, Ana
    Quereda Rodriguez-Navarro, Carlos
    NEFROLOGIA, 2015, 35 (04): : 412 - 413
  • [25] In Vitro Activities of Ceftazidime-Avibactam, Aztreonam-Avibactam, and a Panel of Older and Contemporary Antimicrobial Agents against Carbapenemase-Producing Gram-Negative Bacilli
    Vasoo, Shawn
    Cunningham, Scott A.
    Cole, Nicolynn C.
    Kohner, Peggy C.
    Menon, Sanjay R.
    Krause, Kevin M.
    Harris, Kelly A.
    De, Partha P.
    Koh, Tse Hsien
    Patel, Robin
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2015, 59 (12) : 7842 - 7846
  • [26] Ceftazidime/Avibactam Resistance in Carbapenemase-Producing Klebsiella pneumoniae
    Cui, Qiaozhen
    Wang, Chen
    Wang, Qichen
    Qin, Juanxiu
    Li, Min
    Ding, Baixing
    Shen, Zhen
    EMERGING INFECTIOUS DISEASES, 2023, 29 (11) : 2398 - 2400
  • [27] In vitro activity of cefiderocol against comparators (ceftazidime-avibactam, ceftazidime-avibactam/ aztreonam combination, and colistin) against clinical isolates of meropenem-resistant Klebsiella pneumoniae from India
    Borde, Kalyani
    Kareem, M. A.
    Sharma, Ratna Mani
    Dass, S. Manick
    Ravi, Vedantham
    Mathai, Dilip
    MICROBIOLOGY SPECTRUM, 2023, 11 (05):
  • [28] Ceftazidime-avibactam treatment in bacteremia caused by OXA-48 carbapenemase-producing Klebsiella pneumoniae
    Lima, O.
    Sousa, A.
    Longueira-Suarez, R.
    Filgueira, A.
    Taboada-Martinez, C.
    Portela-Pino, C.
    Nodar, A.
    Vasallo-Vidal, F.
    Martinez-Lamas, L.
    Perez-Landeiro, A.
    Rubianes, M.
    Perez-Rodriguez, M. T.
    EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2022, 41 (09) : 1173 - 1182
  • [29] Activity of aztreonam/avibactam and ceftazidime/avibactam against Enterobacterales with carbapenemase-independent carbapenem resistance
    Mushtaq, Shazad
    Vickers, Anna
    Woodford, Neil
    Livermore, David M.
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2024, 63 (03)
  • [30] Acetylcysteine increases sensitivity of ceftazidime-avibactam–resistant enterobacterales with different enzymatic resistance to ceftazidime-avibactam in vitro and in vivo
    Zeyu Huang
    Yijia Han
    Xiaotuan Zhang
    Yao Sun
    Yuzhan Lin
    Luozhu Feng
    Tieli Zhou
    Zhongyong Wang
    BMC Microbiology, 23